U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07700160) titled 'First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors' on July 07.
Brief Summary: This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.
Study Start Date: July 13
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors...